Case Conference / Multidisciplinary Board
Schedule, case briefs, evidence and decision recording for multidisciplinary reviews.
Participants
Case queue
52-year-old woman newly diagnosed with invasive ductal carcinoma of the left breast, ER/PR positive and HER2 negative, following an abnormal screening mammogram. Genomic panel identifies an actionable PIK3CA variant and a BRCA2 variant of uncertain significance. Case scheduled for multidisciplinary tumor board.
Breast Cancer Diagnosis and Staging Guideline (Demonstration Excerpt)
Illustrative Oncology Practice Network · Level 1A
Biomarker-Directed Therapy Selection in Hormone-Receptor-Positive Breast Cancer (Demonstration Excerpt)
Illustrative Precision Oncology Alliance · Level 1B
- ?Has the multidisciplinary tumor board discussion been scheduled?
- ?Has the genetic counselling referral for the BRCA2 finding been completed?
- ?Does the non-mass enhancement on MRI need additional sampling?
Radiology and Pathology agents show strong concordance confirming invasive ductal carcinoma with a BI-RADS 5 correlate. Oncology and Evidence & Guidelines agents agree the PIK3CA mutation supports consideration of targeted combination therapy pending multidisciplinary review. The BRCA2 variant remains of uncertain significance — the Pathology agent has explicitly abstained from asserting its relevance until germline testing is complete.